Unicycive Therapeutics (UNCY) Competitors $0.50 -0.03 (-5.66%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends UNCY vs. ZNTL, ATAI, DMAC, CABA, SCLX, ADAP, CRBU, ATOS, CADL, and ABOSShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Zentalis Pharmaceuticals (ZNTL), Atai Life Sciences (ATAI), DiaMedica Therapeutics (DMAC), Cabaletta Bio (CABA), Scilex (SCLX), Adaptimmune Therapeutics (ADAP), Caribou Biosciences (CRBU), Atossa Therapeutics (ATOS), Candel Therapeutics (CADL), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Zentalis Pharmaceuticals Atai Life Sciences DiaMedica Therapeutics Cabaletta Bio Scilex Adaptimmune Therapeutics Caribou Biosciences Atossa Therapeutics Candel Therapeutics Acumen Pharmaceuticals Unicycive Therapeutics (NASDAQ:UNCY) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Does the media favor UNCY or ZNTL? In the previous week, Unicycive Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.28 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is UNCY or ZNTL more profitable? Unicycive Therapeutics' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A N/A -34.98% Zentalis Pharmaceuticals N/A -44.22%-35.61% Which has more risk & volatility, UNCY or ZNTL? Unicycive Therapeutics has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Do insiders & institutionals believe in UNCY or ZNTL? 40.4% of Unicycive Therapeutics shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, UNCY or ZNTL? Unicycive Therapeutics has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K69.40-$30.54M-$1.05-0.48Zentalis PharmaceuticalsN/AN/A-$292.19M-$2.72-1.22 Does the MarketBeat Community prefer UNCY or ZNTL? Zentalis Pharmaceuticals received 29 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Unicycive Therapeutics an outperform vote while only 62.64% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUnicycive TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Zentalis PharmaceuticalsOutperform Votes5762.64% Underperform Votes3437.36% Do analysts recommend UNCY or ZNTL? Unicycive Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 924.80%. Zentalis Pharmaceuticals has a consensus target price of $10.78, indicating a potential upside of 224.63%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Zentalis Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 SummaryUnicycive Therapeutics beats Zentalis Pharmaceuticals on 16 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.48M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.489.93114.8115.14Price / Sales69.40396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book-4.555.324.665.02Net Income-$30.54M$153.56M$119.06M$225.46M7 Day Performance20.51%0.13%0.80%0.37%1 Month Performance31.19%15.23%5.65%3.57%1 Year Performance-14.51%41.14%36.75%29.43% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.0099 of 5 stars$0.50-5.7%$5.13+924.8%-10.7%$50.48M$680,000.00-0.489Gap UpZNTLZentalis Pharmaceuticals1.5732 of 5 stars$2.73+1.1%$10.78+294.8%-79.7%$191.99MN/A-1.00160Upcoming EarningsATAIAtai Life Sciences2.0102 of 5 stars$1.06-5.4%$10.50+890.6%-9.2%$187.93M$310,000.00-2.6583Positive NewsDMACDiaMedica Therapeutics1.6105 of 5 stars$4.37+0.2%$7.00+60.2%+86.4%$186.38MN/A-8.2520Positive NewsCABACabaletta Bio2.4755 of 5 stars$3.55-6.3%$28.10+691.5%-74.8%$185.14MN/A-1.8750SCLXScilex2.8666 of 5 stars$0.96+2.1%$11.33+1,080.2%-46.3%$180.63M$46.74M-0.6780Gap UpADAPAdaptimmune Therapeutics2.9169 of 5 stars$0.73+4.3%$3.38+366.3%+48.1%$179.10M$141.46M-2.07449Short Interest ↓News CoverageCRBUCaribou Biosciences2.1193 of 5 stars$1.96-0.5%$11.25+474.0%-38.3%$178.01M$34.48M-1.41100Upcoming EarningsATOSAtossa Therapeutics1.1609 of 5 stars$1.38-2.1%$6.25+352.9%+110.3%$177.32MN/A-6.578Analyst ForecastNews CoverageCADLCandel Therapeutics1.5752 of 5 stars$5.28-2.4%$11.00+108.3%+486.7%$173.58M$120,000.00-3.1260Negative NewsABOSAcumen Pharmaceuticals3.5984 of 5 stars$2.88-5.0%$9.00+212.5%+49.7%$173.03MN/A-2.5751News CoverageGap Up Related Companies and Tools Related Companies Zentalis Pharmaceuticals Alternatives Atai Life Sciences Alternatives DiaMedica Therapeutics Alternatives Cabaletta Bio Alternatives Scilex Alternatives Adaptimmune Therapeutics Alternatives Caribou Biosciences Alternatives Atossa Therapeutics Alternatives Candel Therapeutics Alternatives Acumen Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UNCY) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UNCY Stock Alerts